Articles tagged with 'Export-LatestNews' | Bayer

Real-world evidence (RWE) research results on treatment utilization and pathways in women with menopausal symptoms via poster presentations on the CHAPTER natural menopause study, CHAPTER i-menopause study and REALISE study / These poster presentatio...

Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and eff...

Agreement with UK-based NIAB to acquire their strawberry pipeline and commercial portfolio / Focus on large-scale professional strawberry growers to meet growing consumer and retail demand / The program will continue to be based in Kent, UK...

Climate impacts estimated to have reduced farmer incomes by 15.7% on average over the past two years / Most pressing short-term challenges dominated by economic uncertainty and cost concerns / Yet 4 in 5 farmers have already taken or plan to take ste...

The investment supports Bayer’s sustainability goal to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030 / The company’s facility in Turku will utilize automation, robotics, and digital tec...

New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds

Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...

Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m2 gross floor area / R&D facility offers space for 200 empl...

New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s tes...

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year, exploratory clinical endpoints improved overall, with ...

Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...

Berlin, August 22, 2023 – Bayer today announced Juergen Eckhardt MD, MBA as the new Head of Business Development & Licensing / Open Innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. He will join the Pharmaceuticals Exec...

Leverkusen, August 21, 2023 – The Supervisory Board of Bayer AG has unanimously appointed Heike Prinz to Bayer’s Board of Management effective September 1, 2023. She will become the company’s Chief Talent Officer and Labor Director. This follows the ...

Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomize...

Group sales fall by 8.2 percent (Fx & portfolio adj.) to 11.044 billion euros / EBITDA before special items: 2.527 billion euros (minus 24.5 percent) / Crop Science business down significantly, mainly due to sharp decline in glyphosate volumes and pr...

Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9.

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to...

Leverkusen, July 24, 2023 – The Bayer Group adjusted its full-year outlook for 2023 downward on Monday, mainly due to a significant further decline in sales of glyphosate-based products.For full-year 2023, Bayer now anticipates sales of between 48.5 ...

Helminth infections affect poorest and most deprived communities / More than 1.5 billion people infected with at least one soil-transmitted helminth worldwide

Beijing, July 10, 2023 –Bayer and Peking University (PKU) will collaborate to foster the translation of basic pharmaceutical research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across the ...

Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...

R&D strategy poised to translate higher quality and productivity in Bayer’s innovation model into long-term growth in four key focus areas with high unmet patient needs / Shifting to breakthrough innovations based on new scientific approaches, platfo...

Bayer’s projects in India, Bangladesh, Kenya, and Mexico/Honduras improve growers’ income and quality of life significantly, new analysis confirms / Majorities of around 70 to 90 percent of smallholder farmers surveyed report positive social benefits...

Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year / Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment ...

Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) featuring high relaxivity with the potential for a substantially lower gadolinium (Gd) dose / QUANTI clinical development program includes two Phase III studies in ad...

Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...

Partnership will enhance clinical adoption of artificial intelligence (AI) in medical imaging  / AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity of radiology interventions...

Expectation to tap into more than 100 billion euros of value in accessible and ag-adjacent markets  / Unparalleled pipeline with estimated peak sales potential of more than 30 billion euros to promote regenerative agricultural practices and enable fa...

New post hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will validate a model predicting the risk of chronic kidney disease (CKD) progression in adults at all stages of CKD / Update on FINEGUST study, descri...

Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio / High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing ...